Is Mycoplasma Hominis an STD? Symptoms & Treatment

Mycoplasma hominis is sexually transmitted, but calling it an “STD” (or STI) oversimplifies what the organism actually does. Unlike gonorrhea or chlamydia, M. hominis commonly lives in the genital tract of healthy adults without causing any symptoms at all. It behaves more like an opportunistic hitchhiker: it spreads through sexual contact, colonizes the mucous membranes of the urogenital tract, and in most people just sits there. The trouble starts when conditions shift in its favor, at which point it can drive bacterial vaginosis, pelvic inflammatory disease, pregnancy complications, and fertility problems. That dual identity as both harmless resident and occasional pathogen is what makes M. hominis tricky to classify and even trickier to decide when to treat.

Normal Flora or Sexually Transmitted Infection

M. hominis was first isolated from the human genital tract in 1937, and researchers have known for decades that it is one of the most common bacteria living on urogenital mucous membranes. A large Korean study analyzing over 59,000 samples found an overall M. hominis positivity rate of about 5.5%, with women testing positive far more often than men (roughly 9% of women versus about 4.5% of men).¹ Another study found M. hominis in about 18% of women attending a sexually transmitted disease clinic, with the number of lifetime sexual partners being a strong predictor of colonization, especially among women not using barrier contraception.² So the link to sexual activity is clear, but colonization alone does not equal disease.

This is precisely why the European STI Guidelines Editorial Board has taken a cautious stance. Their position statement explicitly recommends against routine testing and treatment for M. hominis in either symptomatic or asymptomatic men and women, noting that asymptomatic carriage is common and most colonized people never develop any disease.³ That said, genital mycoplasma infections have increasingly been recognized as STIs, with some researchers placing them alongside gonorrhea, syphilis, and chlamydia in terms of clinical importance.¹ The tension between those two positions reflects a genuine scientific disagreement about where to draw the line between a commensal organism and a pathogen.

How M. Hominis Spreads

Sexual contact is the primary route. The correlation between number of sexual partners and colonization rates has been documented repeatedly, and nonbarrier contraception methods (anything other than condoms) increase the likelihood of acquiring it.² Condom use reduces the risk, though it does not eliminate it entirely, since M. hominis can colonize areas of the genital tract beyond what a condom covers.

The other important route is vertical transmission, meaning a colonized mother can pass M. hominis to her baby during delivery. One study of 165 pregnant women found that 15% carried M. hominis vaginally, and of those, 60% transmitted the organism to their newborns.⁴ In most neonates the colonization clears on its own, but in rare cases, particularly with premature infants, it can cause serious infections.

Symptoms in Women

Most women colonized with M. hominis never notice a thing. When symptoms do appear, they tend to cluster around a few conditions.

Bacterial vaginosis (BV) is the most common association. BV is not a simple infection caused by a single bug; it is a shift in the entire vaginal microbial community. M. hominis appears to play a specific role in that shift, working in concert with Gardnerella vaginalis. One study found that co-infection with both organisms was present in about 61% of women with BV, compared to only about 9% of women with a healthy vaginal microbiome.⁵ The loads of the two organisms rose together in a positively correlated fashion, suggesting a genuine synergy rather than coincidental co-occurrence. Symptoms of BV typically include thin grayish-white discharge with a fishy odor, vaginal irritation, and sometimes burning during urination.

Pelvic inflammatory disease (PID) is a more serious concern. M. hominis can be isolated from the vagina or cervix in half to three-quarters of PID patients, a far higher rate than in other clinical groups, and about a quarter of PID patients develop a measurable antibody response to the organism during the course of the disease.⁶ Experimental work in primates has shown that M. hominis introduced into the reproductive tract can spread from the cervix upward, probably through blood vessels and lymphatic channels, producing inflammation of the tissue surrounding the fallopian tubes.⁷ PID symptoms include lower abdominal or pelvic pain, abnormal vaginal discharge, painful intercourse, fever, and irregular bleeding.

Pregnancy Complications

M. hominis has been linked to several adverse pregnancy outcomes. The organism can invade the amniotic cavity, and researchers have identified a specific gene in M. hominis that is significantly associated with colonization of the upper reproductive tract during pregnancy and with preterm birth.⁸ Animal studies have confirmed that M. hominis acting as a sole pathogen can cause chorioamnionitis (infection of the fetal membranes), preterm delivery, and fetal lung inflammation, and that the severity of these problems worsens the longer the infection persists in utero.⁹

For pregnant women, these findings mean that M. hominis is not just a passive bystander. When it reaches the amniotic cavity it can trigger a robust inflammatory response that directly contributes to preterm labor and fetal injury. That said, the vast majority of women who carry M. hominis in their vaginal flora go on to have uncomplicated pregnancies. The risk rises when the organism migrates upward, which it does in a minority of colonized women.

Effects on Male Health and Fertility

M. hominis is detected far less often in men than in women. One study of 390 men with urethritis found M. hominis in only about 1% of cases, compared to nearly 15% for the related organism Ureaplasma urealyticum.¹⁰ So M. hominis is a rare cause of urethritis (burning or discharge from the penis during urination) in men, though it has been isolated from cases of nongonococcal urethritis.¹¹

Where M. hominis appears to matter more in men is fertility. A systematic review and meta-analysis pooling data from eleven studies found that infertile men carrying M. hominis had significantly lower sperm concentration, progressive motility, viability, and normal sperm shape compared to uninfected men.¹² In practical terms, all four of the major semen quality measures were worse in infected men. A separate clinical study found that M. hominis was detected in about 14.5% of infertile men, compared to only 3.6% of fertile controls. After antibiotic treatment, most semen parameters improved to normal ranges, oxidative stress markers dropped, and the wives of more than half of the treated men became pregnant within four months.¹³ That recovery after treatment strongly suggests the infection itself was the problem, not just a coincidental finding in infertile men.

The Gardnerella and Trichomonas Connection

M. hominis rarely acts alone. Its strongest co-detection partners are Gardnerella vaginalis, Ureaplasma urealyticum, and Trichomonas vaginalis. A large epidemiological study found that the single strongest predictor of finding M. hominis was the concurrent presence of Gardnerella, with a co-detection rate roughly ten times higher than expected by chance.¹⁴ Ureaplasma urealyticum and Trichomonas vaginalis were also strongly associated, with co-detection rates about six and five and a half times higher than baseline, respectively.

The Trichomonas relationship is particularly interesting. M. hominis can actually live inside Trichomonas vaginalis cells, forming an endosymbiotic relationship. Sheltered within the protozoan, the bacterium gains protection from both the immune system and from antibiotics circulating in the surrounding tissue.¹⁵ This means that treating M. hominis without addressing a concurrent Trichomonas infection can leave a reservoir of bacteria hiding inside the protozoan, potentially leading to recurrence.

How M. Hominis Avoids the Immune System

One reason M. hominis can persist for so long without being cleared is that it has evolved a sophisticated set of immune evasion strategies. These include varying its surface proteins so the immune system struggles to recognize it consistently, forming biofilms that shield bacterial communities from immune cells, and directly dampening the activity of the immune cells trying to eliminate it.¹⁶ Add in molecular mimicry, where the bacterium’s surface molecules resemble host molecules closely enough to confuse immune surveillance, and you have an organism that is remarkably good at flying under the radar. This helps explain why colonization can persist for months or years without provoking noticeable symptoms.

Diagnosis

Detecting M. hominis is not as straightforward as swabbing for gonorrhea or chlamydia. Mycoplasmas lack a cell wall, which makes them invisible on a standard Gram stain. They also grow slowly in culture, taking two to five days when they grow at all. PCR-based testing has largely replaced culture as the preferred diagnostic method. Studies comparing the two approaches have consistently shown PCR to be faster and more sensitive. One head-to-head comparison found that PCR picked up M. hominis in specimens that culture missed about 16% of the time, while culture only occasionally identified positive samples that PCR had missed.¹⁷ A real-time PCR method targeting a specific M. hominis gene detected positive samples in 55 out of 153 urogenital specimens, compared to only 45 by culture.¹⁸ Multiplex PCR panels that test for several genital mycoplasma species simultaneously have also shown good sensitivity and specificity.¹⁹

Despite PCR’s advantages, there is a practical catch. Most standard STI panels ordered during routine screening do not include M. hominis. Unless a clinician specifically requests testing for genital mycoplasmas, the organism will be missed. Given the European guidelines’ recommendation against routine testing of asymptomatic people, testing is typically reserved for situations where symptoms suggest possible mycoplasma involvement and common STI screens have come back negative, or during workups for unexplained infertility, recurrent BV, or complications in pregnancy.

Treatment and Antibiotic Resistance

Treating M. hominis is complicated by an unusual antibiotic resistance profile. The organism is naturally resistant to the macrolide antibiotics most people associate with treating respiratory and some genital infections, such as erythromycin and azithromycin (the common Z-pack).²⁰ This is an intrinsic resistance, meaning it is built into the organism’s biology, not something it has recently acquired. Azithromycin, often prescribed empirically for urethritis or cervicitis, simply will not work against M. hominis.

The standard first-line treatment is a tetracycline, most often doxycycline, typically given as a course lasting one to two weeks. In clinical practice this works for most people, but resistance is emerging. A French surveillance study identified the tet(M) gene in all tetracycline-resistant M. hominis isolates, and fluoroquinolone resistance was also documented, driven by mutations in the genes encoding the enzymes the drugs target.²¹ When doxycycline fails, fluoroquinolones such as levofloxacin or moxifloxacin are the typical second-line options.²² Moxifloxacin is generally reserved for the toughest cases, since resistance to it requires mutations in two separate genes simultaneously, which is less common.²³

Because M. hominis is often found alongside other organisms, treatment sometimes needs to address those co-infections too. If Trichomonas vaginalis is present, metronidazole or tinidazole for the Trichomonas is essential, both to clear that infection and to eliminate the intracellular reservoir where M. hominis can hide. When treating couples for infertility linked to M. hominis, both partners typically receive antibiotics to prevent re-infection through sexual contact.

Neonatal Infections

While M. hominis in adults is usually a nuisance at worst, the picture can be different for newborns. The organism commonly colonizes the genitourinary tract of adult women and can reach the neonate during delivery.²⁴ In most newborns, colonization resolves without intervention. But in premature infants, M. hominis has been reported to cause meningitis, a serious central nervous system infection. These cases are rare: fewer than ten were reported over a 20-year period in the medical literature as of one review’s publication.²⁵ The challenge is that because mycoplasmas do not show up on routine bacterial cultures used in neonatal intensive care, these infections can be missed or diagnosed late, leading to worse outcomes. When recognized, neonatal M. hominis meningitis has been treated successfully with intravenous chloramphenicol, among other agents.

Extragenital Infections in Immunocompromised People

Outside the genital tract, M. hominis occasionally causes infections in people whose immune systems are weakened. Septic arthritis (joint infection) is the most commonly reported extragenital complication. It tends to occur in three situations: the postpartum period, after urinary tract procedures, or in patients on immunosuppressive medications.²⁶ One case report described a young patient who developed hip joint infection and an abscess after receiving rituximab, a drug that suppresses part of the immune system.²⁷ These extragenital cases are rare enough that many clinicians may not think to look for M. hominis, and the organism’s difficulty growing in standard culture further contributes to delayed diagnosis. For organ transplant recipients, people on chemotherapy, or anyone taking medications that suppress immunity, an unexplained joint infection or abscess that does not respond to typical antibiotics should prompt consideration of mycoplasma involvement.

Why M. Hominis Is Not Treated the Same as Chlamydia or Gonorrhea

If you have been told you tested positive for M. hominis, your first instinct might be to compare the situation to testing positive for chlamydia. But the clinical approach is very different. Chlamydia is treated whenever it is detected, because the rate of complications in untreated people is high and the organism is never considered part of normal flora. M. hominis, by contrast, is a normal resident of the genital tract in a substantial percentage of sexually active adults, and colonization alone is not considered a reason to prescribe antibiotics.³

Treatment is warranted when M. hominis is linked to active symptoms or a specific clinical problem: recurrent BV that is not responding to standard metronidazole, signs of PID when other causes have been excluded, unexplained male infertility with M. hominis detected in semen, or pregnancy complications involving intra-amniotic infection. In these situations, targeted treatment with doxycycline (or a fluoroquinolone if needed) can make a real clinical difference. The fertility data are especially compelling, with semen parameters improving across the board and pregnancy rates rising sharply after successful eradication.¹³ For asymptomatic carriers, the risk of driving antibiotic resistance through unnecessary treatment outweighs the uncertain benefit of eradication.